SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization may be delayed.

Drug Requested: Hemangeol[®] (propranolol HCl) **oral solution**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:	
	Date of Birth:
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	
DEA OR NPI #:	
DRUG INFORMATION: Authoriz	
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight:	Date:

Dosing Regimen: 0.15 mL/kg (0.6 mg/kg) twice daily, increase to 0.3 mL/kg (1.1 mg/kg) twice daily after 1 week, then to a maintenance dose of 0.4 mL/kg (1.7 mg/kg) twice daily

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- □ Member has a diagnosis of proliferating infantile hemangioma
- □ Member's age range is between 5 weeks and 5 months
- □ Member weighs at least 2 kilograms
- □ Provider attests the member does NOT have any of the following contraindications to therapy:
 - □ Known hypersensitivity to propranolol or excipients
 - □ Asthma or history of bronchospasm
 - □ Bradycardia (heart rate < 80 beats/minute)

- □ Greater than first degree heart block
- Decompensated heart failure
- \Box Blood pressure < 50/30 mmHg
- □ Pheochromocytoma

Reauthorization Approval: 6 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- □ Member continues to meet all initial request criteria
- □ Member has previously been successfully treated with Hemangeol for 6 months resulting in complete or nearly complete resolution of the target hemangioma but has experienced a recurrence

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. *<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>*